TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04576169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Debridement
Description: Wrist arthroscopy can be performed with or without irrigation. In the debridement arm, a central or radial TFCC tear found during arthroscopy is debrided with a shaver. Portals are closed either with sutures or with medical tape. Immediate mobilization of the wrist is allowed after the operation. Participants are provided with instructions for home exercises, and they are advised to commence the exercises two weeks post-operation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo surgery
Description: Diagnostic wrist arthroscopy can be performed with or without irrigation. A central or radial TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed either with sutures or with medical tape. The procedure is performed in general or regional anesthesia in operating room. Participants are not able to see to the operation area or monitor. They will listen to music with noise-cancelling headphones throughout the operation. The operative time will be matched, with the surgeon simulating a debridement procedure. Immediate mobilization of the wrist is allowed after the operation. Participants are provided with instructions for home exercises, and they are advised to commence the exercises two weeks post-operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic or Open Repair
Description: An ulnar TFCC tear found during wrist arthroscopy is sutured to the capsule or fovea with one of the separately defined methods choosed by the treating hand surgeon. The procedure is performed in general or regional anesthesia in operating room. Wounds are closed and standardized post-operative treatment is started after six weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: An ulnar TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Physiotherapy exercises of wrist and DRUJ stabilizers is started after two weeks.
Study: NCT03263377

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: The school feeding intervention
Description: The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: The school feeding intervention
Description: The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium.
Study: NCT00054119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cositecan
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT05613335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement
Description: Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement
Description: Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement
Study: NCT01876199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intense follow up
Study: NCT02807324

Intervention type: OTHER
Intervention: Venapunction
Description: The only invasive procedure is a venapunction where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).

Intervention type: OTHER
Intervention: Venapunction
Description: The only invasive procedure is a venapunction where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).
Study: NCT02423473

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft
Description: Periodontal surgical technique to treat gingival recessions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft
Description: Periodontal surgical technique to treat gingival recessions
Study: NCT02807324

Intervention type: OTHER
Intervention: Venapunction
Description: The only invasive procedure is a venapunction where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).

Intervention type: OTHER
Intervention: Venapunction
Description: The only invasive procedure is a venapunction where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).

Intervention type: OTHER
Intervention: Venapunction
Description: The only invasive procedure is a venapunction where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).

Intervention type: OTHER
Intervention: Venapunction
Description: The only invasive procedure is a venapunction where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).
Study: NCT04364542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block
Description: The patient lies supine in beach chair position with surgical drapes on. The anatomical landmarks are outlined and the infiltration spot is identified. The block is performed with 10 ml ropivacaine 0.75%.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Nerve Block
Description: The patient lies supine position with the head turned to the contralateral side to the block. A linear high-frequency ultrasound probe is used for identifying the roots of supraclavicular brachial plexus using the traceback technique. The block is performed with 15 ml ropivacaine 0.5%.
Study: NCT06181188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients randomized to the midazolam and fentanyl arm will receive 25mcg incremental doses for procedural sedation
Study: NCT02423473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Composite resin restoration (Filtek Supreme - 3M)
Description: Restorative procedure do treat tooth structure loss
Study: NCT00512135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin) (20 units)
Description: Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.
Study: NCT00059683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical cerclage
Description: Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
Study: NCT01800877

Intervention type: DRUG
Group type: OTHER
Intervention: Vasopressors

Intervention type: DRUG
Group type: OTHER
Intervention: Vasopressors
Study: NCT04364542

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff repair
Description: Conventional arthroscopic rotator cuff repair.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair
Description: Conventional arthroscopic rotator cuff repair.
Study: NCT00623909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AvicennaTM class IV laser application
Description: AvicennaTM class IV laser for application over the skin of human subjects in the treatment of post-thoracotomy pain syndrome. Six sessions, twenty minutes applications over a period of six weeks.
Study: NCT02044276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipegfilgrastim
Description: 6 mg
Study: NCT00822029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOSAMAX
Description: patient receiving one tablet (oral use) 70 mg Fosamax by week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: patient receiving one tablet (oral use) placebo by week
Study: NCT02044276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: 6 mg
Study: NCT00765323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide Implant
Description: 84 mg octreotide subcutaneous implant for 6 months
Study: NCT01388621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg/BW d1 + 15 q4w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
Study: NCT00765323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandostatin LAR Depot
Description: Injections of Sandostatin LAR (dose range \~10-40 mg every 28 days)
Study: NCT02726009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study: NCT01195389

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Resonator
Description: Treatment group vs. Placebo group
Study: NCT01477827

Intervention type: OTHER
Intervention: None - observational study
Study: NCT01195389

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resonator
Description: Treatment group vs. Placebo group
Study: NCT00552526

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic diet
Description: Ketogenic diet is a very strict high fat diet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiepileptic drug (AED)
Description: An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
Study: NCT01480271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 ng GSK2445053
Description: 2ng GSK2445053 administered intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20ng GSK2445053
Description: 20ng GSK2445053 administered intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100ng GSK2445053
Description: 100ng GSK2445053 administered intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200ng GSK2445053
Description: 200ng GSK2445053 administered intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400ng GSK2445053
Description: 400ng GSK2445053 administered intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000ng GSK2445053
Description: 1000ng GSK2445053 administered intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2000ng GSK2445053
Description: 2000ng GSK2445053 administered intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4000ng GSK2445053
Description: 4000ng GSK2445053 administered intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intranasally
Study: NCT03877237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
Study: NCT02086526

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.
Study: NCT00916422

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergen extract (Phleum pratense)
Description: Subcutaneous immunotherapy with modified extract of Phleum pratense. A subcutaneous monthly treatment.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous monthly treatment
Study: NCT04575038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brequinar
Description: Dihydroorotate dehydrogenase inhibitor (DHODHi)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT02703883

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BWST
Description: BWST (six weeks, 3 times/week)
Study: NCT03786601

Intervention type: OTHER
Intervention: Observation
Description: The participants were assigned to different groups according to the results of HPV detection.
Study: NCT02204683

Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept
Description: Intravitreal aflibercept
Study: NCT03517774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Printed Socket
Description: Twenty participants will be fitted with a 3D Printed socket created using 3DPrintAbility hardware and software. To do this, a 3D model of the participants residual limb will be generated which will be used to create the 3D printed sockets. These 20 participants will also receive standard care for prosthetic fitting at SJR. The fittings will be done by one prosthetist. Our team will compare the feasibility, function, quality and stability of the prosthetics through quantitative, economic and qualitative analyses. All fittings will be done under the supervision of a qualified Sunnybrook prosthetist who has previous experience with using 3D printed technologies for creation of prosthetics.
Study: NCT02856451

Intervention type: BIOLOGICAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT00384358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CPM
Description: one time injection of 3-5 mL test article at time of internal fracture fixation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CPM
Description: one time injection of 3-5 mL test article at time of internal fracture fixation

Intervention type: OTHER
Group type: OTHER
Intervention: surgical intervention alone
Description: surgical internal fixation of fracture defines the standard of care group
Study: NCT00667719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 300 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 12.5 mg and 25 mg capsule
Study: NCT03618082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesic agent guided by ANI (Interventional Group)
Description: Anesthesic agent guided by ANI (Interventional Group) The remifentanil administration will be piloted by the ANI, as well as the prophylactic administration of morphine at the end of the intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesic agent guided by ANI (Interventional Group)
Description: Anesthesic agent guided by ANI (Interventional Group) The remifentanil administration will be piloted by the ANI, as well as the prophylactic administration of morphine at the end of the intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of the lowest effective concentration of desflurane (Interventional Group)
Description: Administration of the lowest effective concentration of desflurane (Interventional Group) Desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of the lowest effective concentration of desflurane (Interventional Group)
Description: Administration of the lowest effective concentration of desflurane (Interventional Group) Desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC).
Study: NCT01684449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Rapamycin
Description: Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).~Every three weeks until disease progression or unacceptable toxicity. The treatment will last for 6 cycles if there is not progression or intolerable toxicity.~Additionally, there will be a pharmacokinetic study in a minimum of 9 patients treated with the drug combination.
Study: NCT02360410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Yourself App with Feedback
Study: NCT03582501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure
Description: Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
Study: NCT03893409

Intervention type: OTHER
Description: this is a observation study, no any intervention in patients

Intervention type: OTHER
Description: this is a observation study, no any intervention in patients
Study: NCT02778568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Stretching exercises
Study: NCT04191174

Intervention type: OTHER
Intervention: Hyperpolarized 129Xe MRI
Description: Hyperpolarized 129Xe MRI to evaluate ventilation heterogeneity

Intervention type: OTHER
Intervention: Technegas V SPECT
Description: Technegas V SPECT to evaluate ventilation heterogeneity

Intervention type: OTHER
Intervention: Sputum Induction
Description: Sputum induction to evaluate luminal cellular inflammation
Study: NCT02149550

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NF135 n=5
Description: Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
Study: NCT01156181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical discharge removal
Description: Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
Study: NCT04040127

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord blood stem cells
Description: Umbilical cords are collected from eligible donors at the time of delivery and transported to the processing facility on ice (2-8℃) in Dulbecco's Modified Eagle Media (DMEM). Cords are processed immediately under aseptic conditions and MSCs are collected for culture. Culture is maintained this way until the target number of cells has been reached, at which point passaged cells are suspended in Stem Cellbanker (Amsbio, Cambridge, MA) and frozen at -80℃.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: saline solution used to rinse the canal.
Study: NCT01248884

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: 3 doses, intramuscular into left thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13®
Description: 3 co-administered doses, intramuscular into right thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13®
Description: 3 co-administered doses, intramuscular into right thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13®
Description: 3 co-administered doses, intramuscular into right thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK217744
Description: 3 doses, intramuscular into left thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK217744
Description: 3 doses, intramuscular into left thigh
Study: NCT01100164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zopiclone
Description: Zopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
Study: NCT03149094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBSM-SMI
Description: The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBSM-SMI control
Description: this group will receive the LifeSum app.
Study: NCT01721018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV1716 Intra-pleural delivery
Study: NCT00003011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marimastat
Description: 10 mg PO BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg PO BID